Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America
NCT ID: NCT04227457
Last Updated: 2024-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
700 participants
OBSERVATIONAL
2018-07-25
2023-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America
NCT07192991
A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases
NCT03427541
Factors Determining the Prognosis in NSCLC Stage IV
NCT04306094
A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort of Patients With Lung Cancer.
NCT07279948
Therapeutic and Prognostic Impact of Circulating Tumor Cells in Peripheral Blood in Patients With Non Small-cell Lung Cancer
NCT01052818
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced NSCLC
* To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC
* To describe treatment responses, progression and survival times.
* To describe reasons for treatment discontinuation
* To identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival;
* To define the patient experience of advanced NSCLC and identify unmet needs in their diagnose and treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time);
3. Histologically or cytologically confirmed advanced NSCLC:
1. Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery);
2. Stage IV metastatic disease (de novo or distant relapse)
4. Any NSCLC histological subtype and molecular mutation;
5. Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
6. Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care;
7. Access to patient medical chart for data collection;
8. Willing and able to provide written informed consent and privacy authorization for the release of personal health information.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Latin American Cooperative Oncology Group
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carlos Barrios
Role: PRINCIPAL_INVESTIGATOR
Latin American Cooperative Oncology Group
Gustavo Werutsky
Role: PRINCIPAL_INVESTIGATOR
Latin American Cooperative Oncology Group
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro Oncologico Riojano
La Rioja, Rioja, Argentina
Instituto De Oncologia De Rosario
Santa Fe, Rosário, Argentina
Centro Medico San Roque
Córdoba, Tucumán Province, Argentina
CRIO
Fortaleza, Ceará, Brazil
CLION
Salvador, Estado de Bahia, Brazil
NOB
Salvador, Estado de Bahia, Brazil
Hospital Sírio- Libanês
Brasília, Federal District, Brazil
ICTr
Curitiba, Paraná, Brazil
Hospital de Câncer de Londrina
Londrina, Paraná, Brazil
Hospital de Caridade de Carazinho
Carazinho, Rio Grande do Sul, Brazil
CPO
Porto Alegre, Rio Grande do Sul, Brazil
HCPA
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Moinhos de Vento
Porto Alegre, Rio Grande do Sul, Brazil
Hospital Mãe de Deus
Porto Alegre, Rio Grande do Sul, Brazil
Clínica Reichow
Blumenau, Santa Catarina, Brazil
CNT Itajaí
Itajaí, Santa Catarina, Brazil
Barretos
Barretos, São Paulo, Brazil
COI Américas
Rio de Janeiro, , Brazil
INCA
Rio de Janeiro, , Brazil
AC Camargo
São Paulo, , Brazil
IBCC
São Paulo, , Brazil
Fundación Arturo López Pérez
Providencia, Santiago Metropolitan, Chile
Clínica del Country
Chapinero, Bogota D.C., Colombia
Oncomedica
Montería, Departamento de Córdoba, Colombia
Hospital Pablo Tobon Uribe
Robledo, Medellín, Colombia
Centro Médico Nacional Siglo XXI
Mexico City, Not Aplicable, Mexico
INCan
Mexico City, Not Aplicable, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LACOG 0116
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.